INTRODUCTION
============

Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common optic neuropathy of the elderly that causes sudden visual loss \[[@R1]\]. Disease usually affects the patients over age of 50 and causes painless and unilateral visual loss. Fifteen % of patients with NAION developed the disease in the fellow eye within 5 years \[[@R2]\]. NAION is a multifactorial disease in which some systemic diseases may act as predisposing or precipitating factor including arterial hypertension, nocturnal arterial hypotension, diabetes mellitus, ischemic heart disease, cerebrovascular accidents and arteriosclerosis \[[@R3]\].

Today, there is still no well-established treatment for patients with NAION. Ischemic optic neuropathy decompression trial (IONDT) reported that spontaneous visual acuity improvement has been observed in 43% of patients within six months of disease onset \[[@R4]\]. In 2008, Hayreh & Zimmerman \[[@R5]\] showed that early treatment of NAION with 80 mg of oral prednisone therapy improved both the visual acuity and visual field in their nonrandomized-controlled study. Some researchers injected intravitreal triamcinolone acetonide instead of systemic steroids in order to to avoid systemic steroid side-effects \[[@R6],[@R7]\]. However, intravitreal steroids have well-known steroid-related ocular side effects, such as cataract progression and glaucoma. On the other hand, anti-vascular endothelial growth factor (VEGF) agents may be theoretically helpful as they reduce vascular permeability and thereby decrease optic nerve edema. Bennet *et al*. \[[@R8]\] were the first to perform intravitreal bevacizumab in a NAOIN patient. They reported a significant visual acuity gain and visual field improvement with rapid resolution of disc edema. Recently, including our pilot study, some researchers injected ranibizumab for the treatment of acute NAION and obtained some degree of functional and anatomic benefit \[[@R9]-[@R11]\].

In this study, we aimed to report the one-year result of 0.5 mg intravitreal ranibizumab injection in 17 eyes of 16 patients with acute NAION.

SUBJECTS AND METHODS
====================

Clinical data of seventeen eyes of 16 consecutive patients with a visual loss history of 15 days or less were retrospectively evaluated. Diagnosis of NAION was based on the history of sudden visual loss, edematous optic disc appearance and characteristic visual field defects. Complete blood cell count, erythrocyte sedimentation rate and C-reactive protein analysis were obtained to exclude arteritic type of anterior ischemic optic neuropathy. Patients received a complete eye examination, including visual acuity testing, color vision evaluation with Ishihara's test, slit-lamp examination, Goldmann applanation tonometry, fundus examination, Humphrey's automated perimetry central (30-2 central threshold test) (Model 750 Humphrey Field Analyzer II, Carl Zeiss Meditec, Dublin, Calif., USA), and overall retinal nerve fiber layer thickness (RNFLT) analysis with Heidelberg Spectralis optical coherence tomography (OCT) (Spectralis HRA+OCT; Heidelberg Engineering, Heidelberg, Germany) prior to injection and at each visit. The natural disease course and various treatment options were discussed in detail with the patients and after obtaining the informed consent, 0.5 mg Ranibizumab (Lucentis, Novartis Pharma Stein AG, Stein, Switzerland) was given intravitreally under topical anesthesia (Proparacaine Hydrochloride) 4 mm away from the limbus in phakic eyes and 3.5 mm away from the limbus in pseudophakic eyes in the operating room. All patients were re-examined at the first week, first, third and six months and first year after the injection. Statistical analysis was performed by using SPSS 15 program and Wilcoxon test.

RESULTS
=======

The characteristics of patients and visual acuities are shown in the Table **[1](#T1){ref-type="table"}**.

In our group, 6 patients had diabetes(37%), 4 patients had hypertension (25%), one patient had sleep-apnea syndrome.

After a single dose of ranibizumab injection, visual gain was reported in 14 of 17 eyes. In two eyes, visual acuity was minimally reduced and no change was noted in the remaining eye with an initial visual acuity of hand motions. While pre-injection mean best -corrected visual acuity (BCVA) was 1.45 ±0.88 log Mar unit, post-injection mean BCVA was 1.00±0.68, 0.86 ±0.70, 0.80 ±0.71, 0.77 ±0.70, 0.77 ±0.70 log Mar unit respectively at the first week, first month, third month, sixth month and first year. In all patients, the mean RNFLT dramatically decreased after the injection during the follow- up. While pre-injection mean RNFLT was 210 ±38 µm, post-injection mean RNFLT was 162.11±40.2, 94±27, 71.23±22.5, 63 ±19 and 57 ±18 µm respectively at the first week, first month, third month, sixth month and first year.

Color vision and RNFLT changes are summarized in Table **[2](#T2){ref-type="table"}**.

In Fig. (**[1](#F1){ref-type="fig"}**) (Eye number 3) and Fig. (**[2](#F2){ref-type="fig"}**) (eye number 8) the color fundus pictures, RNFLT analysis and visual field tests illustrate the kind of improvement patients experienced.

Visual fields improved in nine eyes and remained stable in eight eyes at the end of one year.

No injection related complication was noted during the follow-up period.

DISCUSSION
==========

Although the exact mechanism and location of ischemia is still unclear, the small vessel circulatory disturbance of the optic nerve head is the likely scenario. The optic nerve head blood supply derives from an anastamotic arterial circle that originates from the short posterior ciliary arteries. Fluorescein angiographic studies demonstrated that the ischemia is the result of an insufficiency in the paraoptic branches of short posterior ciliary arteries \[[@R12]\].

The role of VEGF in NAION has not been established yet. Ischemia, which plays a role in the pathogenesis of ION, may likely to increase of VEGF and this may alter the vasopermeability and vasogenic edema of the optic nerve head. As the patients with a small cup to disk ratio are predisposed to NAION swelling may cause compression and infarction of the previously unaffected segments of the optic nerve head by creating a sort of compartment syndrome in a structurally crowded optic disc and result in apoptosis of retinal ganglion cells \[[@R13]-[@R16]\]. Treatment modalities are mostly empirical and encompass a wide range of agents presumed to act on thrombosis or on the disc edema itself \[[@R9]\]. As, vascular endothelial growth factor increases the vascular permeability besides stimulating angiogenesis, anti-VEGF agents may have a potential to lessen optic disc edema \[[@R17],[@R18]\]. Also a recent study reported that subretinal fluid was present in approximately 10% of NAION cases and this might contribute to visual loss. So employing anti-VEGF agents may have a rationale in such patients to recover useful vision \[[@R18]\].

Bennet *et al*. \[[@R8]\] treated a 84 year-old woman with unilateral NAION of 3 weeks' duration with a single intravitreal 1.25 mg bevacizumab injection. They demonstrated that optic nerve head edema reduced substantially and visual acuity improved. They also noted thinning of initially increased RNFLT with Stratus OCT 3. After this report, some authors published their experience with intravitreal bevacizumab injection in a small number of patients with acute NAION in a retrospective fashion \[[@R19],[@R20]\]. Recently, Rootman *et al*. \[[@R20]\] compared the results of 1.25 mg intravitreal bevacizumab injection with natural history of NAION in their non-randomized controlled clinical trial. Twenty-five patients were enrolled (17 eyes were treated and 8 eyes were served as control) in their study. They found no difference between the injection and control group regarding the change in visual field, visual acuity, or RNFL thickness. (measured with Cirrus OCT) Furthermore, two of their 17 treated eyes experienced a second NAION episode. The first was four days after the injection and the second was discovered outside of the study period.

There are only a few case series on the intravitreal ranibizumab injection for the treatment of acute NAION. Our preliminary report on four eyes treated with 0.5 mg intravitreal ranibizumab, showed promising results after a follow-up of 3 months. All patients experienced visual gain \[[@R10]\]. Pece *et al*. \[[@R9]\] reported the results of three acute NAION cases who were treated with intravitreal ranibizumab injection. In all patients, they observed an early resolution of optic disk swelling noted immediately after the first week of injection however visual acuity and perimetric improvement did not accompany. Samant *et al*. \[[@R11]\] evaluated the effect of single intravitreal ranibizumab injection in six acute NAION patients. They performed the injection within the fifteen days of presentation and all six patients experienced visual improvement one week after the injection. Spectral domain OCT demonstrated a reduction in peripapillary thickness by an average of 230 μm at one month.

An unanswered question was whether the time lapse between the episode and anti-VEGF agent injection mattered or not? Natural history data shows that visual acuity may worsen progressively over 2 weeks and then become stable \[[@R13]\]. Animal studies suggest that the therapeutic window for acute NAION may be as long as 2 to 3 weeks \[[@R18]\]. Visual dysfunction appears to reach a plateau around the time that optic disk edema is decreased and optic atrophy ensues \[[@R21]\]. Hayreh & Zimmerman \[[@R5]\] indicated a two-week therapeutic window for the employement of systemic steroids. Based on these informations, we elected to perform the intravitreal injection at maximum 15 days after the onset of the disease.

Another controversial aspect of intravitreal anti -VEGF agents in the treatment of acute NAION is the possible role of anti-VEGF agents by themselves on inducing or facilitating acute NAION \[[@R22]-[@R25]\]. In one of these reports, a patient who had a small cupless disc experienced an episode of NAION two weeks after the injection of bevacizumab \[[@R24]\]. In a second report, an episode of NAION was noted in a patient with diabetic macular edema three weeks after the bevacizumab injection \[[@R23]\]. These findings may be coincidental or related to anti-VEGF activity. Mansour *et al*. \[[@R25]\] suggested that potential mechanisms include the vasoconstrictor effect of the anti-VEGF agents, an increase in intraocular pressure from the intravitreal injection and the exacerbation of systemic hypertension from the stress of the procedure. As ranibizumab has a shorter vitreous half-life than bevacizumab (2.88 days versus 4.32) \[[@R26]-[@R28]\] it can be speculated that ranibizumab can be a better choice over bevacizumab in eyes with acute NAION if an anti-VEGF agent will be injected.

The possibility of spontaneous recovery during the natural course of acute NAION does not enable us to attribute high percentage of the visual gain in our study eyes to intravitreal ranibizumab injection. Though spontaneous visual acuity improvement has been observed in 43% of patients within six months of disease onset in ischemic optic neuropathy decompression trial (IONDT) no visual improvement was seen in 45% of patients and even further visual decline was noted in 12% of the cases.^4^ So it can be only speculated that intravitreal ranibizumab injection might have altered the natural disease course positively and helped us to achieve a better visual outcome in our study population. However, we did not have a control group. When the disease course was explained in detail, none of our patients agreed to stay without any treatment.

A randomized controlled study in a larger group of patients is necessary to reach a more reliable conclusion. In light of our study, we feel that intravitreal ranibizumab injection may be offered to patients with acute NAION.
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![Eye number 3, color fundus picture, retinal nerve fiber layer thickness evaluation and visual field test obtained at preinjection (a), one week (b), one month (c), three months (d), six months (e) and one year (f) after the injection.](TOOPHTJ-7-58_F1){#F1}

![Eye number 8, color fundus picture, retinal nerve fiber layer thickness evaluation and visual field test obtained at preinjection (a), one week (b), one month (c), three months (d), six months (e) and one year (f) after the injection.](TOOPHTJ-7-58_F2){#F2}

###### 

Pre and Postinjection Visual Acuity Changes in the Study Group

  Eye No   Age/Sex/Eye   Time Between Visual Loss And Intravitreal Injection    Visual Acuity (Log Mar Unit)                               
  -------- ------------- ----------------------------------------------------- ------------------------------- ------ ------ ------ ------ ------
  1        62/F/L        2 days                                                1,60                            0,52   0,52   0,52   0,40   0,52
  2        90/M/L        2 days                                                1,60                            1,30   1,30   1,30   1,0    1,0
  3        57/M/L        3 days                                                0,30                            0,10   0,0    0,0    0,0    0,0
  4\*      51/M/R        3 days                                                1,60                            0,70   0,52   0,52   0,52   0,52
  5        45/F/R        4 days                                                1,60                            1,0    0,70   0,70   0,70   0,70
  6        61/M/L        6 days                                                1,0                             1,0    0,52   0,52   0,52   0,52
  7        52/F/R        7 days                                                1,60                            1,0    0,40   0,40   0,52   0,30
  8        63/M/R        7 days                                                0,70                            0,30   0,22   0,30   0,22   0,22
  9        55/F/R        7 days                                                3                               1,60   1,60   1,30   1,30   1,30
  10       62/F/L        9 days                                                0,30                            0,70   0,70   0,70   0,52   0,52
  11       54/M/R        9 days                                                0,30                            0,52   0,52   0,30   0,30   0,40
  12       61/F/L        10 days                                               1,0                             0,40   0,40   0,1    0,1    0,1
  13\*     51/M/L        10 days                                               3                               1,60   1,60   1,60   1,60   1,60
  14       71/F/R        11 days                                               1,60                            1,60   1,0    1,0    1,0    1,0
  15       55/F/L        11 days                                               1,6                             1,0    1,0    0,70   0,70   0,70
  16       64/F/L        12 days                                               3                               3      3      3      3      3
  17       41/F/R        15 days                                               1                               0,70   0,70   0,70   0,70   0,70

Patient with the bilateral involvement.

###### 

Pre and Postinjection Color Vision and RNFLT Changes in the Study Group

  Eye No.         Color Vision   RNLFT (µm)                                                                            
  --------------- -------------- ------------ --------- -------- --------------- -------- --------- --------- -------- -----
  Pre-Injection   1 week         1 month      6 month   1 year   Pre-Injection   1 week   1 month   6 month   1 year   
  1               0/21           0/21         4/21      4/21     3/21            242      91        46        43       42
  2               0/21           0/21         0/21      0/21     0/21            223      131       84        65       58
  3               20/21          21/21        21/21     21/21    21/21           202      153       95        79       68
  4               0/21           1/21         0/21      1/21     1/21            199      199       102       56       42
  5               0/21           2/21         3/21      1/21     1/21            163      203       100       41       45
  6               1/21           12/21        12/21     13/21    13/21           163      156       118       111      103
  7               0/21           0/21         0/21      0/21     0/21            289      185       73        53       62
  8               4/21           16/21        17/21     17/21    17/21           183      259       93        53       48
  9               0/21           0/21         0/21      0/21     0/21            234      167       78        52       48
  10              19/21          18/21        18/21     17/21    21/21           159      123       76        62       59
  11              16/21          15/21        7/21      16/21    16/21           212      186       176       56       45
  12              1/21           1/21         4/21      20/21    20/21           192      139       115       99       97
  13              0/21           0/21         0/21      0/21     0/21            241      165       93        56       64
  14              0/21           0/21         0/21      0/21     0/21            237      154       105       44       38
  15              0/21           0/21         0/21      1/21     1/21            264      137       68        59       46
  16              0/21           0/21         0/21      0/21     0/21            223      255       81        57       56
  17              1/21           20/21        20/21     21/21    21/21           156      210       106       85       63

[^1]: This study was presented in part at the ARVO meeting, Seattle, WA, USA May 5-9, 2013.
